Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Victor Soto

Internal Medicine San Juan, PR Medical Doctor

NPI 1811451222 CMS profile 11259792

University District Hospital, Centro Medico, San Juan, PR 00921

Open in the dashboard

General payments

$4,379

105 records reported · program years 2021–2025

Research payments

$1,376

Paid to them · 8 records reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Victor Soto of San Juan, PR is reported in the CMS Open Payments database as having received $4,379 across 105 general payments and $1,376 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,953 73
2024 General $1,165 27
2024 Research $1,376 8
2023 General $246 4
2021 General $15 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Victor Soto
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Victor Soto were reported at $2,953. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Victor Soto Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $15 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $246 $149 $45–$519 $160
2024 $1,165 $154 $47–$537 $164
2025 $2,953 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,339 29 payments
  2. United Therapeutics Corporation $418 5 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $370 11 payments
  4. Merck Sharp & Dohme Corporation $303 11 payments
  5. Jazz Pharmaceuticals Inc. $286 7 payments
  6. Genzyme Corporation $232 9 payments
  7. Actelion Pharmaceuticals US, Inc. $191 2 payments
  8. Caris MPI, Inc. $186 3 payments
  9. Sanofi-Aventis U.S. LLC $175 2 payments
  10. E.R. Squibb & Sons, L.L.C. $144 2 payments
  11. Other $735 24 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,115 102 payments
  2. Education $264 3 payments
Products named General payments · program years 2021–2025
  1. TEZSPIRE $649 10 payments
  2. FASENRA $615 16 payments
  3. DUPIXENT $373 10 payments
  4. OFEV $299 8 payments
  5. UPTRAVI $291 6 payments
  6. XYWAV $286 7 payments
  7. OPSUMIT $216 3 payments
  8. MI CANCER SEEK $186 3 payments
  9. CAPVAXIVE $171 4 payments
  10. WINREVAIR $167 8 payments
  11. Other $1,439 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Regeneron Pharmaceuticals, Inc. $1,376 8 payments

Records

113 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record